Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana

Item

http://www.wikidata.org/entity/Q48898788

Q48898788

about

177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer.Current status of theranostics in prostate cancer.68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence.The role of PSMA PET scans in salvage therapy planning.Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.Clinical implications of PET/CT in prostate cancer management

P2860

Q42371612-D82A5AEA-1090-46AA-A63D-BD4FBC66379E Q47241139-77504786-D645-4A30-995B-1B053A24147D Q47269407-F64D9C2B-12FF-4DA9-821E-2914CFEFFD40 Q48568705-82D9881F-A1F7-4791-9282-8233934F8674 Q49833204-2656E4A7-D851-43C1-AA29-E1C23CA5C85C Q50034009-01725867-59CB-40BD-B8E7-5FD85BE4FBD9 Q50083626-9E62D281-9495-4ECB-B4AC-E60ECA7346F9 Q55118858-68ADA8FA-84F4-4320-981F-8F1A2C1D683A Q59137133-5DFAF20D-4BA3-40B1-94FB-037A98606FF2

P2860

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana

Item

http://www.wikidata.org/entity/Q48898788

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Clinical impact of 68 Ga-prost ...... rative intent: preliminary ana

@en

Clinical impact of 68 Ga-prostate-specific membrane antigen

@nl

type

Item

label

Clinical impact of 68 Ga-prost ...... rative intent: preliminary ana

@en

Clinical impact of 68 Ga-prostate-specific membrane antigen

@nl

prefLabel

Clinical impact of 68 Ga-prost ...... rative intent: preliminary ana

@en

Clinical impact of 68 Ga-prostate-specific membrane antigen

@nl

P1476

Clinical impact of 68 Ga-prost ...... rative intent: preliminary ana

@en

P2093

Alexandre Peltier

http://www.w3.org/2001/XMLSchema#string

Carlos Artigas

http://www.w3.org/2001/XMLSchema#string

Eric Hawaux

http://www.w3.org/2001/XMLSchema#string

Fouad Aoun

http://www.w3.org/2001/XMLSchema#string

Francois-Xavier Otte

http://www.w3.org/2001/XMLSchema#string

Ibrahim Biaou

http://www.w3.org/2001/XMLSchema#string

Julien Grosman

http://www.w3.org/2001/XMLSchema#string

Ksenija Limani

http://www.w3.org/2001/XMLSchema#string

Nicolas Sirtaine

http://www.w3.org/2001/XMLSchema#string

Patrick Flamen

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2016

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.

Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group

A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.

Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.

P304

197-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJU.13739

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27981732

http://www.w3.org/2001/XMLSchema#string

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana

about

P2860

P2860

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698